How to avoid ‘citation fatigue’

In the days after the Trump administration’s declaration that it was ending the opioid epidemic, drug makers were scrambling to find ways to keep their customers on their toes.

The pharmaceutical industry has been grappling with this question for decades.

Its history of marketing and selling opioids to opioid users, which has included marketing a drug that can be administered by injection to help with pain, has long been a source of frustration among those who struggle with addiction.

Some researchers say they are increasingly concerned about the opioid industry’s attempts to manipulate its customers, and that there are significant risks to this.

For example, in the last few months, some drug companies have quietly started to push opioids to treat a variety of ailments that they had previously avoided, including anxiety and post-traumatic stress disorder.

But they are also trying to capitalize on a problem that has become particularly acute since the opioid crisis began.

One of those painkillers, oxycodone, is becoming increasingly popular as a treatment for chronic pain.

Some experts are concerned that it could become a gateway drug for those with addiction to prescription opioids, which are increasingly used to treat chronic pain in the United States.

And some researchers say that it is likely that other pharmaceutical companies will also start using opioids to manage pain in patients who have not been prescribed opioids.

What does the data say about the safety of oxycodones?

Oxycodones are the most widely used painkiller in the world.

But studies have also shown that some other opioids can be more effective than oxycodans.

Oxycodone has a relatively short half-life.

OxyContin, a drug sold by Purdue Pharma, is 10 times more potent than oxyacetazolamide, the main ingredient in oxycodan.

Oxycontin is also often used in a more controlled setting, while oxyacetosolamide is often given to patients in the intensive care unit.

Oxyacetazoles have been shown to be more harmful than oxyhydrocodone, which is the main active ingredient in OxyContin.

The most recent study, which followed people for about a year, found that people taking oxycodane-based painkillers were at higher risk of heart disease and diabetes.

In the last year, studies have found that oxycodanes may increase the risk of some types of cancer, and may increase lung cancer risk in women.

It is unclear how much of the increase in cancer risk may be linked to the use of oxyacetamol or oxycodanic-based drugs.

However, one study of patients taking oxyacetylmorphine found that it may increase risk of cancer.

And one study found that patients taking fentanyl, the active ingredient of oxymorphone, were at a higher risk for cancer.

Oxymorphone is the active drug in oxymorwatch, a painkiller that is commonly prescribed to treat patients with moderate to severe pain, and is also sold by Pfizer.

Pfizer is the manufacturer of Oxymorwatch.

And it is unclear whether Pfizer, or anyone else, is using oxymorkillers in a way that increases the risk for the drug’s cancer-causing properties.

In addition, there is conflicting data about the effectiveness of oxycodes as a pain treatment.

Some studies have shown that oxycodes can help treat moderate to moderate to painful pain, while other studies have not found evidence that oxybos can be effective.

Some recent research has suggested that oxymorcodone could be useful for people who have pain that is not related to cancer.

But other research has found that Oxycodans might be more useful for certain types of pain, such as migraine headaches, which can cause a severe headache.

The opioid crisis is now in its second year, and it has created new challenges for the pharmaceutical industry.

Many drugmakers have tried to find new ways to address the opioid market, but some are worried about how to manage the crisis.

One such company, the drugmaker Merck, is exploring using oxycodas as an alternative to opioids, but it is uncertain whether that would be effective in some patients.

For now, Merck has opted to stop selling oxycoda-based products.

The other drugmaker, AstraZeneca, is considering moving away from oxycodies altogether, but is taking a wait-and-see approach.

And a number of drugmakers are also testing new approaches to managing their pain.

For instance, in 2016, the company Merck bought Insys, a maker of painkillers that had been developing an injectable drug called Narcan.

This was a breakthrough because it was the first drug to treat people who were addicted to opioid painkillers and who needed Narcan to stop them from dying. However — and this may surprise some opioid users — Narcan has never been approved for use in the U.S. It has been used in several countries, but not in the States.

This means that the opioid painkiller market is still a black box.

And this has caused many painkillers companies to explore ways to avoid